Signals
ADA 2026 findings show diabetes drugs are no longer just chasing glucose
New phase 3 findings presented at ADA 2026 suggest the next wave of cardiometabolic therapies is moving beyond blood sugar control and weight loss, towards broader effects on liver fat, cardiovascular risk markers, sleep apnoea and obesity-related complications.
Risk Prediction Cannot Simply Be Imported From Europe
Personalised Cardiology Needs a Digital Fabric, Not Just More Data
AI Diabetes Tools Need Infrastructure Before Scale
Diabetes Tech Moves From Optional Add-On to Earlier Care
Obesity Care Starts Moving Beyond BMI
Canada’s Generic Semaglutide Approval Tests GLP-1 Affordability
India’s Obesity Campaign Dispute Tests the Line Between Awareness and Promotion
Cyberbullying Becomes a Youth Mental Health Policy Target
Rare Epilepsy Moves Toward Treating the Cause
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.